AxoGen Inc. is an growing regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration. The company has had more than 7,000 surgical implants of its products performed in hospitals and surgery centers across the United States, including military hospitals that serve U.S. servicemen and women.

Turklay believes that the Company is "Hitting an inflection point" and values the company at $8 per share, which is based on an EV/Sales multiple of 5x on estimated 2014 revenues of $25 million; representing an 81% increase over his 2013 revenue estimate of $13.8 million.

His valuation is consistent with his analyst peers and inline with the take-out multiples of regenerative medicine companies that have been purchased by larger medical device companies, have been picked up within the ~5x to ~6x range.

Among the noteable purchases in this space was Royal DSM's (RDSMY.PK) purchase of Kensey Nash was purchased for ~5x sales, Shire's (SHPG) acquisition of Advance Biohealing at ~5.1x sales, Johnson & Johnson's (JNJ) purchase of Synthes for ~5.8x sales. The most expensive purchase was Kinetic Concepts acquisition of LifeCell for $1.7 billion, or ~8.5x sales.

Regenerative medicine continues to be a hot-bed of opportunity for investors. This is because larger med-tech companies with commoditizing products are in search of cutting-edge, high growth technologies to help bolster their top-line growth rates.

For AxoGen, peripheral nerve regenerative represents a pioneering opportunity for the company, which Turklay noted it as a "unique one-stop shop for peripheral nerve repair". AxoGen is the sole player in a peripheral nerve allograft market that is an estimated $1 billion opportunity.

Investors are becoming more aware of Axogen and it's products and business potential. It was recently highlighted on FOX Business News' Varney & Company and was written up in the Wall Street Journal. This has not only been positive for the Company's shares, which are up approximately 88% year-to-date, but more physicians and surgeons are being educated and introduced to the company's products, which will later translate in to improving sales growth.

Investors should keep watch on AxoGen shares.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

AxoGen is an emerging player in the field of regenerative medicine, with a unique focus on the peripheral nerve repair market, which is estimated to be a $1 billion market opportunity.

According to Levy, demand for AxoGen's product portfolio, led by its Avance product, the only commercially-available nerve allograft, has grown significantly over the last 12 months, and he forecasts the Company will deliver 60+% yr/yr sales growth in 2012. The key drivers behind this performance have been the publication of positive clinical data, greater clinician awareness of Avance's benefits, and an expansion of AxoGen's sales and marketing efforts.

Levy also believes that AXGN's recent $20.8 million financing with PDL BioPharma (PDLI) removes a significant overhang that now allows the company to focus its efforts toward growing the business.

AXGN trades at a 2013 Enterprise Value (EV)/Sales multiple of 2.3x, which is an approximately 40% discount to peers which include: Anika Therapeutics (ANIK), Cytomedix (CMXI), Cardiac (CRDC), Cryolife (CRY), BioMimetic , Cytori (CYTX) and MiMedx (MDXG). Levy believes that AXGN current share prices, "does not adequately reflect the growth potential of AXGN's product portfolio." His price target of $5.00 is based on applying the average peer group multiple of 3.5x EV on his 2013 AXGN sales estimate of $14.5 million.

BioMimetic Therapeutics is a development-stage regenerative medicine company focused on the $1+ billion orthobiologics market. Its lead product candidate is Augment which is designed as an alternative to autograft in foot and ankle fusion surgery. The Company recently submitted an ammended PMA which Levy believes improves the Company's chances for receiving FDA approval.

BMTI shares has been under pressure as a result of a January 2012, non-approval letter from the FDA for its Augment product. In July 2012, the Company submitted a PMA application, which according to Levy, addressed all of the information requested by the FDA. Additionally, the Company's patient study, which includes 13,000 patients appears to have allayed carcinogenic concerns with a protein used in Augment.

Levy's $7.50 price target is risk-adjusted and reflects, "a 70% probability that our base case scenario (2H13 Augment approval) occurs and 30% probability for our bear case (2016)".

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Conference dial-in: 877-709-8150

International dial-in: 201-689-8354

Webcast: www.axogeninc.com/investors.html

A webcast replay of the conference call will be available on the Company's website, www.axogeninc.com, under "Investors."

About AxoGen, Inc.
AxoGen (AXGN.OB) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen's products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. For more information, visit our website at www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's principal executive office and operations are located in Alachua, FL.

To receive email alerts directly from AxoGen, please click here www.axogeninc.com/emailalerts.html.

Contacts

COCKRELL GROUP
Rich Cockrell, 212-521-4138
investorrelations@thecockrellgroup.com
www.cockrellgroup.com
or
AxoGen, Inc.
Greg Freitag, 386-462-6856
Chief Financial Officer
InvestorRelations@axogeninc.com

www.axogeninc.com

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Second Quarter 2012 Highlights

• Record revenues of $2.01 million, a 64% increase from second quarter 2011
• Gross profit for second quarter 2012 increased 89% to a record $1.5 million
• Gross profit margins improved to 75% compared to 65% for the same period in 2011

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced revenues for the second quarter ended June 30, 2012 of $2.01 million, a 64% increase over second quarter 2011 revenues of $1.65 million.

"We are pleased to once again have a record quarter," commented Karen Zaderej, Chief Executive Officer of AxoGen, Inc. "We continue to gain traction in the market by building awareness of our products and I am particularly pleased with the level of receptivity we're experiencing with surgeons to our entire product portfolio. The handling characteristics and growing body of clinical data continue to drive adoption of Avance® Nerve Graft. In addition, during this quarter we saw solid growth of our AxoGuard® Nerve Protector and AxoGuard® Nerve Connector. AxoGen's portfolio of products for nerve repair have unique features that are making them the product of choice with many surgeons."

Revenues

Revenues for the period were $2.01 million, a 64% increase, compared to $1.23 million in 2011. The improved results were primarily due to improving sales and marketing efforts which have been focused on the development of new accounts as well as improved penetration into key accounts.

Sequentially, revenues improved 22% from the reported first quarter 2012 of $1.65 million.

Gross Profit

Gross profit reached $1.51 million, an 89% increase, for second quarter 2012 up from $0.80 million reported for the same period 2011. The higher gross profit was the result of increased revenues combined with lower manufacturing cost. The gross profit margin increased to 75% compared to 65% for the same quarter last year.

Sales and Marketing Expenses

During the period sales and marketing expenses increased to $1.58 million from $0.95 million reported during the same period last year. The higher expenses were primarily the result of the companies continued expansion and support of direct sales and independent distributors. As of the end of the period, the Company reported 16 direct and 21 independent sales representatives and distributors.

Research and Development Expenses

Research and development expenses increased to $0.37 million during the quarter. Substantially all of the research and development expenses relate to expenditures for clinical activity.

General and Administrative Expenses

General and administrative expenses decreased to $1.14 million for the period, compared to $1.20 million reported last year. These decreases were principally a result of a decrease in legal and consulting services.

Loss From Operations and Net Loss

The Company reported loss from operations of $1.59 million compared to loss from operations of $1.45 reported during the same period in 2011. The Company reported a net loss of $1.03 million, or $0.09 per common share, compared to a net loss of $2.0 million, or $1.65 per common share, reported during the same period in 2011. Net loss was reduced by a non-recurring income tax benefit in the amount of approximately $736,000, representing approximately $.07 per share.

Financial Liquidity

At June 30, 2012, the Company had $4.6 million in cash and cash equivalents, with approximately $4.9 million in debt outstanding. The Company has entered into a two year Interim Revenue Purchase Agreement, pursuant to which the Company received $1.75 million in exchange for the sale of specified future cash royalty payments. As a result of continuing capital needs, and other factors, the Company is considering raising additional funds through public or private equity offerings, debt financings, royalty contracts or other sources.

Earnings Call Information

As previously announced, AxoGen, Inc. management will review second quarter 2012 financials during a conference call scheduled for August 15, 2012 at 11:00 AM Eastern Time. The conference call information is as follows:

A webcast replay of the conference call will be available under the "Investor" tab on the Company's website, www.axogeninc.com.

About AxoGen, Inc.

AxoGen (OTCBB: AXGN) is a leading regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance® Nerve Graft, the only commercially available allograft nerve for bridging peripheral nerve discontinuities (a gap created when the nerve is severed) of up to 70mm in length.

AxoGen's portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen's principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

See notes to condensed consolidated financial statements.

COCKRELL GROUP
Rich Cockrell, 404-942-3369
Investorrelations@thecockrellgroup.com
www.cockrellgroup.com
or
AxoGen, Inc.
Greg Freitag, Chief Financial Officer, 386-462-6856
InvestorRelations@AxoGenInc.com
www.axogeninc.com

Dr. Marco Moran, Dewmar's President and CEO, states, "Based upon what Dewmar's sales force has seen in the field over the past 12 months from accounts across America, as well as information that we have received from distributors from the East to West Coasts, we are confident that our brand is the second most widely distributed relaxation beverage in the U.S. market today. The first is Marley's Mellow Mood. This is primarily due to three key reasons (1) the popularity of their 3 good tasting relaxation teas as opposed to their two carbonated sodas (2) the brand image of iconic reggae master Bob Marley and (3) their investment of over a purported $1 million in combined paid slotting fees and free product to retail chain accounts in 2011." Dr. Moran continues, "As it pertains to carbonated relaxation beverages, based upon our data as well as limited Nielson C-store data, we anticipate Lean Slow Motion Potion™ to be the most widely distributed carbonated relaxation soda brand in convenience stores all across America for the past year."

Moreover, Dewmar reports to have grown their brand over the past 3 years strictly based upon the sheer merits and popularity of the LEAN brand without paying one single dollar for slotting.

Dewmar plans to implement a number of strategies to capture additional market share primarily by strengthening its current and future distribution relationships with a number of its larger beverage distributors -- primarily a number of independent Budweiser and Miller/Coors distribution houses that have strong non-alcoholic beverage management teams. "We anticipate that we can at least double, if not triple, our distribution volumes with our large beer distributors by placing a full-time brand manager with a Lean Slow Motion Potion™ logo wrapped vehicle to work directly within that distributor's market," states Dewmar's President, Dr. Marco Moran.

Historically, numerous beverage industry reports show that full service direct-store-delivery (DSD) distributors primarily perform better in launching new brands when there is full-time staff available to represent the brand and keep the distributors' sales staff on their toes when it comes to promoting the brand to retail managers on a daily basis. Otherwise, new brands tend to get lost in the plethora of all the non-supported brands that the mega-distributors tend to bring on board over the years.

The Thursday, March 22, 2012 edition of CNBC's 'Hot Start Ups' offered a featured segment on relaxation drinks/beverages. During that segment, it was mentioned that as of 2011, the relaxation drink category was driven by almost 70% annual growth over the past five years. An estimated 70 million Americans have trouble sleeping according to that segment. Americans are consuming over $100 billion a year in products that help relax and manage the stresses of life, including wine, beer, pills, and other items. Lean Slow Motion Potion™ offers a safer, healthier and nondrug-induced alternative to the current most popular forms of non-exercise related relaxation and stress relief.

Dewmar currently ships its product to distributors in fifteen states who in turn place LEAN in retail C-store cold vault outlets in at least 28 states throughout the U.S. The Company intends to expand distribution of Lean Slow Motion Potion™ nationally through retailers across the country. The industry analysis company, IBIS World, projects domestic demand for soft drinks to increase over the next five years by more than $2 billion, potentially generating more than $46.8 billion by 2015 (see chart below). (1)

Industry Data

Annual Change

(1) IBISWorld. "Soft Drink Production in the US Industry Report." Obtained June 2010.

Investor Contact: Cockrell Group Rich Cockrell, 877-747-5326 ext. 4InvestorRelations@DewmarInternational.com www.cockrellgroup.com or Company Contact: Dewmar International Marco Moran, Chief Executive Officer, 877-747-5326info@DewmarInternational.com www.DewmarInternational.com

This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Company's expectations, among other things, are dependent upon general economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, its ability to operate its subsidiary companies effectively, need for and availability of additional capital as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's Form 10-Ks and 10-Qs on file with the United States Securities and Exchange Commission.

"We are delighted with the smooth and successful launch of this installation and its performance," said Dr. Vlad Sklyar, president of GYTI. "The customer has invested significant time, money and effort into this project. We understand that it is seeking to expand the current project by replacing multiple lines with a lesser number of gyrotron based lines. We are also in discussions with the customer regarding additional projects and look forward to a long and very fruitful relationship."

About Gyrotron Technology -- (GYTI.PK)
Develops and markets unique industrial heating technologies to a broad range of industries, including glass, solar, and semiconductor. These technologies open new horizons, substantially enhancing productivity and cutting costs by, among other things, applying heat in a dramatically more efficient and effective manner than is possible with legacy technologies.
Please visit our website http://www.gyrotrontech.com/ or go to http://www.gyrotrontech.com/images/gyti.pk%20summary.pdf for GYTI summary information.

Forward-Looking Statements

This release and the materials referred to herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of GYTI. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties inherent herein and in publically available information on GYTI. These risks s uncertainties could cause actual results to differ materially from those indicated in the forward-looking statements.